Ranbaxy Laboratories launches India’s first new drug ‘Synriam’

25 Apr 2012 Evaluate

Ranbaxy Laboratories has launched India’s first new drug ‘Synriam’, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults. At a function held in New Delhi, the Minister of Health and Family Welfare and Minister of Science & Technology and Earth Sciences, Government of India unveiled India's first new drug Synriam with the company dedicating the new age cure for malaria to the nation, on World Malaria Day.

The new drug has been approved by the Drug Controller General of India (DCGI) for marketing in India and conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Synriam provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 percent.

Phase III clinical trials for the drug conducted in India, Bangladesh and Thailand successfully demonstrated the efficacy and tolerability of Synriam as comparable to the combination of artemether and lumefantrine.

Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×